This is another evidence that impairing tumor immune resistance seems to be a useful approach in antitumor therapy and IDO inhibition is effective in restoring immune function in malignancies dependent on T regs stimulation, such as GBM. The gene discussed is IDO1; the disease is glioblastoma.